- Home
- AURA
as of 12-02-2025 3:59pm EST
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.
| Founded: | 2007 | Country: | United States |
| Employees: | N/A | City: | BOSTON |
| Market Cap: | 396.8M | IPO Year: | 2021 |
| Target Price: | $20.33 | AVG Volume (30 days): | 211.6K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.90 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.34 - $9.53 | Next Earning Date: | 11-13-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
AI-Powered AURA Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Aura Biosciences Inc. (AURA)
Chief Medical Officer
Avg Cost/Share
$5.42
Shares
17,109
Total Value
$92,730.78
Owned After
252,685
SEC Form 4
See Remarks
Avg Cost/Share
$6.35
Shares
9,049
Total Value
$57,461.15
Owned After
474,391
SEC Form 4
Senior Vice President, Finance
Avg Cost/Share
$6.35
Shares
896
Total Value
$5,689.60
Owned After
85,662
SEC Form 4
Chief Technology Officer
Avg Cost/Share
$6.35
Shares
12,169
Total Value
$77,273.15
Owned After
197,287
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Hopkins Janet Jill | AURA | Chief Medical Officer | Nov 17, 2025 | Sell | $5.42 | 17,109 | $92,730.78 | 252,685 | |
| de los Pinos Elisabet | AURA | See Remarks | Oct 29, 2025 | Sell | $6.35 | 9,049 | $57,461.15 | 474,391 | |
| Elazzouzi Amy | AURA | Senior Vice President, Finance | Oct 29, 2025 | Sell | $6.35 | 896 | $5,689.60 | 85,662 | |
| Plavsic Mark | AURA | Chief Technology Officer | Oct 16, 2025 | Sell | $6.35 | 12,169 | $77,273.15 | 197,287 |
Compare AURA vs Leading Stocks
See how AURA stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "AURA Aura Biosciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.